MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: NEC Corporation
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

NEC Initiates AI-driven Drug Discovery Business Targeting A Business Valuation of ¥300 Billion by 2025 - First Japan-based company to initiate clinical trials in development of individualized neoantigen vaccines - NEC.com
NEC Initiates AI-driven Drug Discovery Business Targeting A Business Valuation of ¥300 Billion by 2025

 

NewswireToday - /newswire/ - Tokyo, Japan, 2019/05/27 - First Japan-based company to initiate clinical trials in development of individualized neoantigen vaccines - NEC.com. NEC; TSE: 6701

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Engineering / Artificial Intelligence Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

NEC Corporation today announced that it will expand the application of its cutting-edge AI technologies,"NEC the WISE" (*1), to cancer drug development that focuses on advanced immunotherapy as part of enhancing its healthcare business.

As a start, clinical trials for individualized neoantigen (*2) vaccines will be initiated with Transgene SA (Transgene), making NEC the first company in Japan to initiate such trials.

The companies will target head and neck cancer and ovarian cancer with clinical trials that will be conducted in the United States and Europe. In April, an application to the United States Food and Drug Administration's (FDA) Investigational New Drug (IND) program received clearance to proceed with a Phase 1 clinical trial. Application submissions to the UK and France are currently under review. The investigational drug is being jointly developed by NEC and Transgene.

An estimated 18.1 million new cancer cases were diagnosed worldwide in 2018 (*3) and cancer is stated as the leading cause of death in Japan (*4). There are great expectations in the development for better cancer treatments. This applies especially to cancer immunotherapy, which has been hailed as the next generation of cancer treatment, and utilizes a patient's own immune system to fight cancer.

NEC has an established history of working in close collaboration with academic institutions that include Kochi University and Yamaguchi University on research related to cancer drug discovery.

In recent years, the advent of genomic analysis has resulted in a massive growth in genome data, which has required artificial intelligence (AI) in order to be efficiently and accurately processed. NEC is aiming to see its AI-driven drug discovery business valued at ¥300 billion by 2025 through the development of more efficacious and safer immunotherapies.

In the development of individualized neoantigen vaccines, the selection of target neoantigens is crucial. NEC's neoantigen prediction utilizes its proprietary AI, such as graph-based relational learning, which is combined with other sources of data to discover candidate neoantigen targets. NEC comprehensively evaluates the candidate neoantigens with a primary focus placed on its in-house MHC-binding affinity prediction. As such, NEC is able to effectively prioritize the numerous candidate neoantigens identified in a single patient. This unique approach has resulted in NEC's acceptance into the Tumor neoantigEn SeLection Alliance (TESLA) consortium, thereby allowing NEC to actively contribute to this global research initiative which seeks to improve cancer treatment.

NEC is committed to the provision of social solutions that promote an equal and prosperous society that embraces diversity and allows all individuals to play an active role.

"The advent of individualized immunotherapies calls for new business paradigms and thus new types of alliances. We are confident that Transgene and NEC have established a strong technological foundation with great synergies for the co-development of our individualised neoantigen vaccine, TG4050," said Éric Quéméneur, Pharm.D., Ph.D., Executive Vice President and Chief Scientific Officer of Transgene. "We look forward to capitalizing on our synergistic expertise and complementary business development efforts."

*1) NEC the WISE - NEC's cutting-edge portfolio of AI technologies.
*2). Neoantigen: Newly generated cancer antigens associated with genetic mutations in cancer cells. Neoantigens are not expressed in normal cells, but are found only in cancer cells, many of which vary from patient to patient.
*3). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
*4). 2017 demographic statistics from Japan's Ministry of Health, Labour and Welfare.

About NEC Corporation
NEC Corporation (nec.com) is a leader in the integration of IT and network technologies that benefit businesses and people around the world. The NEC Group globally provides "Solutions for Society" that promote the safety, security, efficiency and equality of society. Under the company's corporate message of "Orchestrating a brighter world," NEC aims to help solve a wide range of challenging issues and to create new social value for the changing world of tomorrow.

NEC is a registered trademark of NEC Corporation. All Rights Reserved. Other product or service marks mentioned herein are the trademarks of their respective owners. ©2019 NEC Corporation.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Engineering / Artificial Intelligence Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: NEC Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Engineering / Artificial Intelligence articles,
CATCH Visitors via Your Competitors Announcements!


NEC Initiates AI-driven Drug Discovery Business Targeting A Business Valuation of ¥300 Billion by 2025

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any NEC Corporation securities in any jurisdiction including any other companies listed or named in this release.

Engineering / Artificial Intelligence via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From NEC Corporation / Company Profile


Read Engineering / Artificial Intelligence Most Recent Related Newswires:

US DoD C4ISR 2024 Spend Fueled by Special Operations Command’s Intelligence Finds Frost & Sullivan
ABB Demonstrates Concept of Mobile Laboratory Robot for Hospital of the Future
Leonardo and Ansaldo Energia to Work Together on 'Intelligent Factory' Project
ABB Releases the Newest Extension of their Vacuum Contactor Series
ABB Showcases Next Level in Smart Home Automation At IFA 2019
Onfido Commended by Frost & Sullivan for its Proprietary AI-based Hybrid Identity Verification Solution
Vessel Powered by ABB Azipod® Propulsion Reaches North Pole for the First Time in History
Jio and Guavus Partner on AI-powered Analytics
ABB’s Digital Solution for Shipping Fleets Helps to Further Reduce Fuel Costs and Environmental Footprint
BASF and TU Berlin Launch Artificial Intelligence Cooperation
ABB Launches World’s First Excitation Product Compliant with New European Grid Code
ABB to Modernize Shymkent Oil Refinery, Supporting Digitalization of Kazakhstan
Mazda Drives Engineering Creativity Using Siemens’ Model-based Generative Engineering Tools
CarLabs Earns Acclaim from Frost & Sullivan for its AI-based Customer Engagement and Marketing Platform
SMS Digital and Voith Cooperate to Push IIoT Platform Development

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit Havens Metal Works





 
  ©2019 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)